Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy

被引：0
|
作者：
Sorrentino, J. A. [1 ]
Lai, A. [1 ]
Weiss, J. M. [2 ]
Dragnev, K. H. [3 ]
Owonikoko, T. K. [4 ]
Adler, S. [5 ]
Antal, J. M. [5 ]
Malik, R. K. [5 ]
Roberts, P. J. [1 ]
机构：
[1] G1 Therapeut Inc, Translat Med, Res Triangle Pk, NC USA
[2] Univ N Carolina, Hematol Oncol, Chapel Hill, NC 27515 USA
[3] Dartmouth Hitchcock Med Ctr, Hematol Oncol, Norris Cotton Canc Ctr, Lebanon, PA USA
[4] Emory Univ, Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA
[5] G1 Therapeut Inc, Clin Dev, Res Triangle Pk, NC USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1671P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
    Daniel, D.
    Kuchava, V.
    Bondarenko, I.
    Ivashchuk, O.
    Spigel, D.
    Dasgupta, A.
    Reddy, S.
    Melkadze, T.
    Jaal, J.
    Kudaba, I.
    Hart, L.
    Matitashvili, A.
    Koynov, K. D.
    Yang, Z.
    Wolfe, S. G.
    Malik, R.
    Morris, S. R.
    Antal, J. M.
    Goldschmidt, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
  • [2] Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
    Dragnev, K. H.
    Owonikoko, T. K.
    Csoszi, T.
    Maglakelidze, M.
    Beck, J. T.
    Gomez, M. Domine
    Lowczak, A.
    Fulop, A.
    Hoyer, R. J.
    Hanna, W.
    Lowry, P.
    Aljumaily, R.
    Chiu, V. K.
    Bulat, I.
    Yang, Z.
    Roberts, P. J.
    Antal, J. M.
    Malik, R. K.
    Morris, S. R.
    Weiss, J. M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] UPDATED PFS ANALYSIS OF TORIPALIMAB WITH ANLOTINIB AND CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
    Luo, Hao
    Jian, Dan
    Feng, Yan
    Zhong, Li
    Chen, Qian
    Guan, Wei
    Zhang, Shiheng
    Luo, Jiamin
    Yang, Xueqin
    Gong, Kan
    Xiong, Yanli
    Li, Mengxia
    Xu, Mingfang
    Pu, Yu
    Zhao, Liang
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A490 - A490
  • [4] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [5] Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Myeloprotection effects of trilaciclib in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) receiving chemotherapy-a real-world study
    Chen, Yongxing
    Meng, Chong
    Liu, Lirong
    Liu, Kai
    Chen, Tao
    Yang, Chen
    JOURNAL OF THORACIC DISEASE, 2024, 16 (11)
  • [7] Second-line treatment outcomes in Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients after first-line immuno-chemotherapy
    Wan, Rui
    Fan, Linjie
    Zhong, Jia
    Duan, Jianchun
    Wang, Zhijie
    Hao, Xuezhi
    Wang, Jie
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?
    Elijah, Joseph
    Jain, Prantesh
    Holdsworth, Allison
    Baron, Jeffrey
    Przespolewski, Eugene
    Wang, Katy
    Attwood, Kristopher
    Billias, Christina
    Dy, Grace K.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (09)
  • [9] Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    LUNG CANCER, 2024, 194
  • [10] Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.
    Chen, Lijuan
    Zhao, Yanqiu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345